Avadel Pharmaceuticals (AVDL) Competitors $10.65 +0.27 (+2.60%) Closing price 04:00 PM EasternExtended Trading$10.64 -0.01 (-0.05%) As of 04:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AVDL vs. ACLX, MRUS, ZLAB, SRRK, ACAD, VKTX, SWTX, PTGX, MLTX, and IMVTShould you be buying Avadel Pharmaceuticals stock or one of its competitors? The main competitors of Avadel Pharmaceuticals include Arcellx (ACLX), Merus (MRUS), Zai Lab (ZLAB), Scholar Rock (SRRK), ACADIA Pharmaceuticals (ACAD), Viking Therapeutics (VKTX), SpringWorks Therapeutics (SWTX), Protagonist Therapeutics (PTGX), MoonLake Immunotherapeutics (MLTX), and Immunovant (IMVT). These companies are all part of the "pharmaceutical products" industry. Avadel Pharmaceuticals vs. Its Competitors Arcellx Merus Zai Lab Scholar Rock ACADIA Pharmaceuticals Viking Therapeutics SpringWorks Therapeutics Protagonist Therapeutics MoonLake Immunotherapeutics Immunovant Arcellx (NASDAQ:ACLX) and Avadel Pharmaceuticals (NASDAQ:AVDL) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk. Which has preferable valuation and earnings, ACLX or AVDL? Avadel Pharmaceuticals has higher revenue and earnings than Arcellx. Avadel Pharmaceuticals is trading at a lower price-to-earnings ratio than Arcellx, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArcellx$107.94M36.10-$107.35M-$2.99-23.65Avadel Pharmaceuticals$169.12M6.09-$48.83M-$0.27-39.44 Is ACLX or AVDL more profitable? Avadel Pharmaceuticals has a net margin of -13.58% compared to Arcellx's net margin of -211.46%. Arcellx's return on equity of -35.27% beat Avadel Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Arcellx-211.46% -35.27% -22.73% Avadel Pharmaceuticals -13.58%-36.07%-16.30% Do institutionals & insiders have more ownership in ACLX or AVDL? 96.0% of Arcellx shares are held by institutional investors. Comparatively, 69.2% of Avadel Pharmaceuticals shares are held by institutional investors. 8.4% of Arcellx shares are held by company insiders. Comparatively, 5.2% of Avadel Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has more risk and volatility, ACLX or AVDL? Arcellx has a beta of 0.28, indicating that its stock price is 72% less volatile than the S&P 500. Comparatively, Avadel Pharmaceuticals has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500. Does the media prefer ACLX or AVDL? In the previous week, Avadel Pharmaceuticals had 2 more articles in the media than Arcellx. MarketBeat recorded 4 mentions for Avadel Pharmaceuticals and 2 mentions for Arcellx. Arcellx's average media sentiment score of 1.58 beat Avadel Pharmaceuticals' score of 0.79 indicating that Arcellx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcellx 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Avadel Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate ACLX or AVDL? Arcellx currently has a consensus target price of $111.23, indicating a potential upside of 57.33%. Avadel Pharmaceuticals has a consensus target price of $18.17, indicating a potential upside of 70.58%. Given Avadel Pharmaceuticals' higher probable upside, analysts clearly believe Avadel Pharmaceuticals is more favorable than Arcellx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arcellx 0 Sell rating(s) 0 Hold rating(s) 14 Buy rating(s) 1 Strong Buy rating(s) 3.07Avadel Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryArcellx beats Avadel Pharmaceuticals on 9 of the 17 factors compared between the two stocks. Get Avadel Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AVDL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AVDL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVDL vs. The Competition Export to ExcelMetricAvadel PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.00B$2.42B$5.52B$9.32BDividend YieldN/A1.79%4.25%4.05%P/E Ratio-39.449.1828.1519.68Price / Sales6.09736.93437.63100.28Price / CashN/A160.6835.5357.53Price / Book13.834.698.235.67Net Income-$48.83M$30.99M$3.23B$257.51M7 Day Performance11.52%0.60%-0.01%0.52%1 Month Performance12.11%7.93%5.61%8.84%1 Year Performance-37.02%-5.48%26.52%14.18% Avadel Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVDLAvadel Pharmaceuticals1.8485 of 5 stars$10.65+2.6%$18.17+70.6%-37.3%$1.00B$169.12M-39.4470ACLXArcellx2.4906 of 5 stars$69.92+1.4%$111.23+59.1%+7.6%$3.85B$76.81M-23.3880News CoveragePositive NewsMRUSMerus1.9238 of 5 stars$55.62+2.1%$84.64+52.2%-5.4%$3.85B$36.13M-13.6337News CoverageZLABZai Lab3.2894 of 5 stars$34.28+4.7%$54.28+58.3%+95.5%$3.81B$398.99M-13.771,869SRRKScholar Rock3.0717 of 5 stars$38.59+3.1%$42.67+10.6%+320.8%$3.66B$33.19M-15.25140ACADACADIA Pharmaceuticals4.0819 of 5 stars$21.89+4.3%$27.88+27.3%+22.1%$3.66B$957.80M15.98510Analyst RevisionVKTXViking Therapeutics4.6176 of 5 stars$31.63+1.7%$87.15+175.5%-48.3%$3.55BN/A-27.5020Positive NewsUpcoming EarningsGap UpSWTXSpringWorks Therapeutics1.5998 of 5 stars$46.99flat$52.57+11.9%N/A$3.54B$191.59M-13.78230Positive NewsPTGXProtagonist Therapeutics1.448 of 5 stars$55.23+4.2%$66.10+19.7%+50.5%$3.42B$434.43M73.64120Positive NewsMLTXMoonLake Immunotherapeutics1.7293 of 5 stars$50.86+3.8%$74.50+46.5%+1.6%$3.26BN/A-22.112IMVTImmunovant1.3583 of 5 stars$18.59+2.5%$36.30+95.3%-42.7%$3.18BN/A-6.78120Positive News Related Companies and Tools Related Companies ACLX Competitors MRUS Competitors ZLAB Competitors SRRK Competitors ACAD Competitors VKTX Competitors SWTX Competitors PTGX Competitors MLTX Competitors IMVT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AVDL) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredFirst time revealing what I do with my own moneyMy mom has made 3,400% returns - here’s her 3-Stock Secret' Joel Litman is an accountant. So is his mom, wh...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avadel Pharmaceuticals PLC. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avadel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AVDL Stock Alerts